Key Highlights
- Chemomab agreed to an all-stock Reverse merger with private precision-medicine company Scipher Medicine, under which existing Chemomab shareholders would own only about 32% of the combined entity before a required $30 million financing.
- The deal redirects Chemomab's lead antibody nebokitug away from its original rare liver disease target toward rheumatoid arthritis, using Scipher's PrismRA blood test to select likely responders in a Phase 2 study.
- Chemomab shareholders receive contingent value rights tied to milestones in the original liver disease program, payable only in cash if specific outcomes are met, while the combined company targets a first-half 2028 data readout.
Chemomab Therapeutics Ltd. (NASDAQ:CMMB) spent years building a case for nebokitug, its experimental antibody for a rare and untreatable liver disease. In July 2026 it agreed to hand the wheel to someone else.
On 8 July it announced an all-stock merger with Scipher Medicine Corporation, a private US precision-medicine group best known for PrismRA, a blood test that flags which rheumatoid arthritis patients are unlikely to respond to widely used TNF-inhibitor drugs. The combined Business would take the Chemomab listing and trade on Nasdaq as SCIP.
The deal answers the question hanging over the stock: how a company with roughly $8 million in the bank would pay for a Phase 3 trial. It will not. Nebokitug is being redirected at a larger indication, and Chemomab holders will own a minority of the vehicle running it.
What Happened
Under the agreement filed on Form 6-K, Chemomab will re-domicile from Israel into Delaware, becoming a Subsidiary of a new holding company, Snowdrift Parent Corporation, which then acquires Scipher. Former Scipher securityholders would own about 68% of the combined company on a fully diluted basis and Chemomab shareholders about 32%, before the placement.
The Placement requires gross proceeds of not less than $30 million at a $150 million combined-company valuation, with 100% Warrant Coverage struck at half that valuation. The syndicate is led by Northpond Ventures and includes Khosla Ventures, Blue Owl Healthcare Opportunities and Neuberger-managed funds.
Chemomab shareholders also receive one contingent value right per share, payable in cash only if specified nebokitug milestones are met. Scipher chief executive Dr. Reginald Seeto would lead the combined company, with Chemomab co-founder Adi Mor, PhD, on the board. The plan is a Phase 2 of nebokitug in rheumatoid arthritis on standard 12-week FDA endpoints, with PrismRA selecting patients and topline data guided for the first half of 2028.
Why It Matters
Nebokitug, previously CM-101, is an antibody that neutralises CCL24, a protein driving inflammation and fibrosis, the scarring that destroys organ function. Chemomab had positioned it in primary sclerosing cholangitis, or PSC, a bile-duct disease with no approved treatment: attractive commercially, but a small population and an expensive pivotal trial.
Rheumatoid arthritis is the opposite trade-off: crowded, but enormous. Mor described the target as a $24 billion market, and many RA patients cycle through Biologics that Fail them. Scipher's argument is that its test identifies non-responders in advance, so a Phase 2 can enrol likelier responders.
The structure also fixes a financing problem: cash at closing is expected to fund the combined company into the second half of 2028, past the guided readout.
The Numbers
The most recent reported quarter is the first quarter of 2026, published on 14 May. Cash and short-term deposits were $8.0 million at 31 March, down from $10.4 million at the end of 2025. The net loss narrowed to $1.8 million from $3.3 million as Research and Development spending fell to $0.9 million from $2.5 million, with the SPRING trial winding down.
The 2025 full-year loss was $9.0 million against $13.9 million in 2024. Shares outstanding rose about 52% during 2025, reaching 576,030,200 by 31 March 2026, roughly 7.2 million ADSs. In August 2025 the ADS ratio moved from 1:20 to 1:80, a de facto one-for-four reverse split.
The data underpinning the CVRs come from SPRING, a double-blind Phase 2 in 76 PSC patients dosed intravenously at 10 or 20 mg/kg, or placebo, every three weeks for 15 weeks; 54 of 56 eligible patients continued into an extension to 48 weeks.
In a pre-specified subgroup with moderate to advanced fibrosis, about half the study, nebokitug produced a statistically significant reduction in liver stiffness versus placebo at week 15, with numerical reductions in the ELF score and PRO-C3 sustained to 48 weeks. The results were published in the American Journal of Gastroenterology in November 2025.
What It Means for the Company
Chemomab is effectively being acquired in a reverse merger, contributing its Nasdaq listing and its drug. The 32% stake will be diluted further by the raise and its warrants, so the outcome for existing holders rests on the combined company's performance and on whether the CVRs ever pay.
The PSC programme is not abandoned but is no longer funded internally. Chemomab had secured FDA alignment on a single pivotal Phase 3 with an event-driven endpoint, and nebokitug holds Orphan Drug designation in the US and EU plus FDA Fast Track. HBM Healthcare Investments, with about 12.5% of the shares, has agreed to vote for the merger.
Risks Investors Should Watch
Closing is not assured. The agreement requires majority Shareholder approval, an effective Form S-4, Nasdaq approval of the new listing, Israeli tax rulings, a 50-day Israeli Waiting Period and completion of the placement. Break fees are modest: $2 million if Chemomab terminates for a superior proposal, $500,000 if the vote fails.
If the deal collapses, Chemomab is left with cash guided only through the first quarter of 2027, no Revenue and a Phase 3 it cannot self-fund. The scientific risk is real too: nebokitug has never been tested in rheumatoid arthritis, and anti-fibrotic activity in liver disease does not transfer automatically to joint inflammation.
This is also a micro-cap, with a Market Value near $11 million in late July 2026 and a 52-week range of roughly $1.35 to $4.80. Liquidity is thin and the company has diluted heavily before.
What Comes Next
The nearest milestone is the Form S-4 covering the merger and domestication. As at 14 August 2026 none had appeared on EDGAR; the only filings referencing Snowdrift Parent are the July 6-K and the HBM Schedule 13D. Once it is effective, a shareholder vote follows, then the Israeli waiting period.
The parties expect to close in the fourth quarter of 2026, with an outside date of 31 March 2027. Chemomab has not yet reported second-quarter 2026 results. Beyond closing, the calendar is sparse: launch of the RA study, any PSC partnering announcement, and topline data in the first half of 2028.
Conclusion
Chemomab's merger solves a real problem, roughly $8 million in cash was never going to fund a Phase 3 trial in a rare liver disease, by handing the wheel to a larger, better-funded strategy in a much bigger market. The trade-off is structural: existing shareholders go from owning 100% of a company built around their own drug to roughly 32% of one led by someone else's test and someone else's therapeutic bet, with meaningful additional dilution still to come from the required financing. Whether the original nebokitug data ever pays out now depends entirely on contingent value rights tied to a program the merged company isn't funding internally, and on a shareholder vote and closing conditions that remain unresolved months out.






Please wait processing your request...